Healthcare Industry News:  ciprofloxacin 

Biopharmaceuticals Regulatory

 News Release - November 17, 2006

AMDL Announces Launch of Antibiotic Levofloxacin in China

TUSTIN, Calif., Nov. 17 (HSMN NewsFeed) -- AMDL (Amex: ADL ) announced today that its China subsidiary, Jade Pharmaceutical Inc., has received approval from the China State Food and Drug Administration (SFDA) for the antibiotic levofloxacin.

Levofloxacin is used to treat infections including pneumonia, urinary tract, kidney and skin infection. It is in a class of antibiotics called fluoroquinolones.

Fluoroquinolones are the fastest growing antibacterial class in terms of global revenue and are being used increasingly to treat a broad range of infections. This market is heavily dominated by ciprofloxacin and levofloxacin, which together command 65 percent ($3.3 billion) of global sales.

"China's pharmaceutical market is undergoing tremendous growth and all signs point to a continuation of this trend," said Gary Dreher, AMDL CEO. Jade Pharmaceuticals will manufacture levofloxacin at the Jiangxi Jade Biochemistry Ltd. manufacturing facility in the South China City of Shargro in the Jiangxi Province of China. At present, this product will only be sold in the People's Republic of China.

About AMDL

AMDL, Inc. (Amex: ADL ), headquartered in Tustin, California, with operations in Shenzhen, Jaingxi and Jilin China through its wholly owned subsidiary Jade Pharmaceutical Inc. is an international biopharma company. AMDL together with Jade engages in the development, manufacture and marketing of proprietary pharmaceutical and testing products. More information about AMDL and its additional products can be obtained at www.amdl.com.

Forward-Looking Statements

Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's partners that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.


Source: AMDL

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.